New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDihexa vs Dermorphin

Dihexa vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Dihexa
Recovery & Repair
Dermorphin
Summary
Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
Unknown (limited pharmacokinetic data)
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
Oral, SubQ, Topical
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
5–10 mg
Not established for human use; research doses vary widely
Frequency
Daily
Not established
Key Benefits
  • Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
  • Enhances memory and learning
  • May reverse cognitive decline
  • Improves neuroplasticity and executive function
  • Long-lasting cognitive benefits from short courses
  • Potential therapeutic agent for Alzheimer's
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Headache
  • Irritability
  • Brain fog during washout period
  • Unknown long-term effects (insufficient data)
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With